
Celldex Therapeutics CLDX
€ 27.32
-1.82%
Celldex Therapeutics Gesamtverbindlichkeiten | CLDX
Gesamtverbindlichkeiten Jährlich Celldex Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 55.8 M | 45.3 M | 36.5 M | 26.5 M | 25.2 M | 26.5 M | 28.9 M | 31.7 M | 79.3 M | 118 M | 47.5 M | 36.4 M | 27.3 M | 29.8 M | 29.3 M | 34.7 M | - | - |
Jährliche Entwicklung
Kennzahlen zur Anzeige auswählen
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 118 M | 25.2 M | 42.4 M |
Gesamtverbindlichkeiten Vierteljährlich Celldex Therapeutics
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 72.1 M | 67.8 M | 55 M | 55.8 M | 50.1 M | 37 M | 36.5 M | 45.3 M | 37.3 M | 31.9 M | 30.2 M | 36.5 M | 33.5 M | 21.8 M | 21.8 M | 26.5 M | 23.8 M | 37.9 M | 25.9 M | 25.2 M | 23.5 M | 22.3 M | 24.9 M | 26.5 M | 25.8 M | 23 M | 28.8 M | 28.9 M | 30.5 M | 32.6 M | 34.9 M | 31.7 M | 40.2 M | 50.3 M | 57.3 M | 79.3 M | 100 M | 115 M | 112 M | 118 M | 34.9 M | 36.5 M | 41.9 M | 47.5 M | 34 M | 37.3 M | 32.1 M | 36.4 M | 32.3 M | 32.3 M | 26.9 M | 27.3 M | 24.2 M | 19.1 M | 29.4 M | 29.8 M | 28.8 M | 27.6 M | 28.9 M | 29.3 M | 27.8 M | 26.5 M | 29.3 M |
Quartalsentwicklung
Kennzahlen zur Anzeige auswählen
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 118 M | 19.1 M | 39.6 M |
Gesamtverbindlichkeiten anderer Aktien in der Pharmaeinzelhändler
| Name | Gesamtverbindlichkeiten | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Replimune Group
REPL
|
166 M | $ 23.3 | 4.67 % | $ 2.16 B | ||
|
Фармсинтез
LIFE
|
1.04 B | - | - | - | ||
|
Royalty Pharma plc
RPRX
|
9.91 B | $ 69.47 | 1.02 % | $ 29.9 B | ||
|
Revolution Medicines
RVMD
|
723 M | $ 193.0 | -3.57 % | $ 36.7 B | ||
|
Rhythm Pharmaceuticals
RYTM
|
210 M | $ 113.99 | 0.04 % | $ 7.41 B | ||
|
Codiak BioSciences
CDAK
|
118 M | - | -55.98 % | $ 2.15 M | ||
|
Sana Biotechnology
SANA
|
256 M | $ 2.43 | -1.42 % | $ 615 M | ||
|
Sol-Gel Technologies Ltd.
SLGL
|
7.11 M | $ 61.81 | 0.11 % | $ 172 M | ||
|
Summit Therapeutics
SMMT
|
92.3 M | $ 17.78 | -0.34 % | $ 13.3 B | ||
|
Checkpoint Therapeutics
CKPT
|
20.1 M | - | - | $ 169 M | ||
|
Syndax Pharmaceuticals
SNDX
|
465 M | $ 9.43 | -0.89 % | $ 817 M | ||
|
Spero Therapeutics
SPRO
|
9.9 M | $ 1.01 | -5.61 % | $ 56.6 M | ||
|
Sarepta Therapeutics
SRPT
|
2.21 B | $ 16.4 | -5.54 % | $ 1.64 B | ||
|
Tarsus Pharmaceuticals
TARS
|
219 M | $ 73.9 | 4.32 % | $ 3.09 B | ||
|
Bio-Techne Corporation
TECH
|
719 M | $ 72.83 | -0.01 % | $ 11.4 B | ||
|
Sage Therapeutics
SAGE
|
82.1 M | - | - | $ 527 M | ||
|
Taro Pharmaceutical Industries Ltd.
TARO
|
405 M | - | - | $ 1.62 B | ||
|
Cabaletta Bio
CABA
|
53 M | $ 1.43 | -5.0 % | $ 144 M | ||
|
Forma Therapeutics Holdings
FMTX
|
62.7 M | - | - | $ 958 M | ||
|
Blueprint Medicines Corporation
BPMC
|
881 M | - | - | $ 8.14 B | ||
|
Horizon Therapeutics Public Limited Company
HZNP
|
2.25 B | - | - | $ 26.6 B | ||
|
Tonix Pharmaceuticals Holding Corp.
TNXP
|
32 M | $ 4.12 | -8.35 % | $ 35.1 M | ||
|
Paratek Pharmaceuticals
PRTK
|
344 M | - | - | $ 121 M | ||
|
DBV Technologies S.A.
DBVT
|
64.9 M | $ 11.55 | 4.52 % | $ 1.61 B | ||
|
Gilead Sciences
GILD
|
39 B | $ 170.68 | 0.8 % | $ 212 B | ||
|
Taysha Gene Therapies
TSHA
|
96.4 M | $ 4.28 | -2.06 % | $ 1.37 B | ||
|
ASLAN Pharmaceuticals Limited
ASLN
|
37.9 M | - | -14.27 % | $ 1.7 M | ||
|
Adverum Biotechnologies
ADVM
|
109 M | - | - | $ 86.2 M | ||
|
Unity Biotechnology
UBX
|
31.2 M | - | -33.41 % | $ 3.37 M | ||
|
iTeos Therapeutics
ITOS
|
96.7 M | - | - | $ 411 M | ||
|
Gossamer Bio
GOSS
|
295 M | $ 11.2 | 5.21 % | $ 2.56 B | ||
|
GeoVax Labs
GOVX
|
2.52 M | $ 0.11 | -22.17 % | $ 105 K | ||
|
United Therapeutics Corporation
UTHR
|
784 M | $ 588.33 | 1.01 % | $ 26.1 B | ||
|
Seelos Therapeutics
SEEL
|
38.9 M | - | -47.76 % | $ 6.27 M | ||
|
Vericel Corporation
VCEL
|
133 M | $ 59.02 | 1.08 % | $ 2.97 B | ||
|
Veracyte
VCYT
|
96.4 M | $ 24.05 | -7.21 % | $ 1.89 B | ||
|
Advaxis
ADXS
|
2.3 M | - | -9.65 % | $ 45.9 M | ||
|
GlaxoSmithKline plc
GSK
|
45.2 B | $ 51.25 | -0.56 % | $ 208 B | ||
|
Vir Biotechnology
VIR
|
238 M | $ 13.17 | -3.48 % | $ 1.82 B | ||
|
Viking Therapeutics
VKTX
|
76.7 M | $ 28.67 | -1.1 % | $ 3.23 B | ||
|
Vanda Pharmaceuticals
VNDA
|
162 M | $ 4.07 | -0.49 % | $ 240 M | ||
|
Verrica Pharmaceuticals
VRCA
|
22.4 M | $ 3.55 | -1.11 % | $ 37.8 M | ||
|
Vertex Pharmaceuticals Incorporated
VRTX
|
6.98 B | $ 547.74 | -0.57 % | $ 140 B | ||
|
Kiromic BioPharma
KRBP
|
21.1 M | - | 6.61 % | $ 3.08 M | ||
|
vTv Therapeutics
VTVT
|
25.5 M | $ 20.88 | -1.42 % | $ 83.8 M | ||
|
CNS Pharmaceuticals
CNSP
|
4.1 M | $ 3.81 | -3.3 % | $ 1.69 M | ||
|
Voyager Therapeutics
VYGR
|
56.2 M | $ 1.82 | -8.54 % | $ 107 M | ||
|
Calithera Biosciences
CALA
|
8.28 M | - | -10.95 % | $ 876 K | ||
|
Applied Molecular Transport
AMTI
|
46.6 M | - | - | $ 10.1 M | ||
|
Wave Life Sciences Ltd.
WVE
|
112 M | $ 3.41 | -2.01 % | $ 575 M |